Segment Reporting - Schedule of Operating Expenses by Function (Details) - USD ($)	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating expenses:
Research and development	$ 21,076,000	$ 25,055,000
General and administrative	6,462,000	8,707,000
Total operating expenses	27,538,000	33,762,000
Loss from operations	(27,538,000)	(33,762,000)
Other income, net:
Interest income	635,000	1,452,000
Other income, net	39,000	82,000
Total other income, net	674,000	1,534,000
Net loss before income tax expense	(26,864,000)	(32,228,000)
Income tax expense	0	0
Net loss	(26,864,000)	(32,228,000)
Clinical
Operating expenses:
Research and development	5,947,000	7,798,000
Manufacturing (pre-commercial)
Operating expenses:
Research and development	5,447,000	6,476,000
Research
Operating expenses:
Research and development	5,919,000	6,344,000
Other
Operating expenses:
Research and development	$ 3,763,000	$ 4,437,000